Dementia is estimated to affect 850,000 people in the UK and costs the nation around £23bn a year Innovate UK has awarded ten new projects over £6m in funding to identify, develop and commercialise biomarker clinical tools and technologies for dementia and neurodegeneration. Through Innovate UK’s Small Business Research Initiative, the competition will aid in enhancing clinical trials and precision therapies for patients living with dementia. Estimated to affect 850,000 people in the UK, dementia is a general term for the impaired ability to remember, think or make decisions, which is economically responsible to cost £23bn a year. Alzheimer’s disease, the most common form of dementia, affects one in 14 people over the age of 65 and one in six people over the age of 80. In alignment with the Dame Barbara Windsor Dementia Mission, a government-led effort to develop new precision dementia therapies and solutions in the UK, the ...
Lung cancer is the leading cause of cancer-related deaths globally, with non-small cell lung cancers making up the majority of cases, which are often linked to smoking. When detected early, these cancers are usually confined to the lung, making surgery the preferred initial treatment. However, about 30% of these early-stage patients see their cancer advance to more critical areas, like the lymph nodes and organs, frequently affecting the brain first. This progression necessitates additional treatments such as chemotherapy, targeted drugs, radiation, or immunotherapy. Unfortunately, despite 70% of patients not developing brain metastasis, doctors have lacked the means to predict whose cancer will progress and often opt for aggressive treatments as a precautionary measure. Now, a new study offers hope in improving the approach to treating early-stage lung cancer by achieving the correct balance between proactive intervention and cautious monitoring. In the study, scientists at Washington University School of Medicine in ...
The centre will deliver free training, outreach materials and programmes The University of Birmingham is set to lead UK-wide virtual reality (VR)-assisted training in medicines manufacturing to address critical skills demand in life sciences. Set to benefit future medicine and vaccine makers, the new RESILIENCE Centre for Excellence for UK Medicines Manufacturing Skills Centre aims to deliver free training, outreach materials and programmes. Supported by £4.5m of funding from Innovate UK and the Office for Life Sciences, the centre will be led by an academic consortium of UK universities, including University College London, Teesside University and Heriot-Watt University. The training centre aims to work with healthcare and pharmaceutical organisations to provide a single-entry point for training and career input, which includes a pipeline of continuing professional development courses. Hundreds of students across the UK are set to benefit from the training developed by the RESILIENCE Centre, including VR and mixed ...
Every year, missed hospital appointments are estimated to cost the NHS £1.2bn The NHS has announced that it’s set to roll out artificial intelligence (AI) to help improve waiting times for elective care and reduce the number of missed appointments. New data has shown that 6.4% of over 125 million outpatient appointments across the NHS in England last year were not attended by the patient, specifically for physiotherapy, cardiology, ophthalmology, trauma and orthopaedics. Additionally, missed appointments are predicted to cost the NHS a total of £1.2bn, annually. Created by Deep Medical, the AI software uses algorithms and anonymised data to predict missed appointments and uses a range of external insights as to why, such as the weather, traffic, jobs and back-up bookings. Piloted for the last six months at Mid and South Essex NHS Foundation Trust, the software will expand to ten more NHS trusts following the success of the ...
The platform delivers digitalised patient data to improve clinical trials and development Phesi has announced that its artificial intelligence (AI)-driven Trial Accelerator platform has reached a critical milestone of now containing global data from more than 100 million patients. The volume will allow sponsors to access data on patients with over 4,000 indications, plan more successful trials and simulate clinical development activity more accurately. Phesi’s Trial Accelerator works to deliver digitalised patient data to enhance or replace those collected from clinical trials. Across the past two decades, data has been collated from product and disease registries, electronic health records, medical claims data and data gathered from around 100,000 dynamically updated sources. The platform powers the Phesi Patient Access Score, Diversity, Equity and Inclusion Data Service and the Digital Patient Profile. “We have been gathering and structuring a wealth of data for sponsors and clinical trial planners,” said Dr Gen Li, ...
In the study, the Lymphoma Artificial Reader System accurately detected 90% of lymphatic cancersResearchers from Chalmers University of Technology in Sweden have developed a new computer model using artificial intelligence (AI), which successfully identifies signs of lymphatic cancer. The model was developed in collaboration with researchers from Memorial Sloan Kettering Cancer Center, Chalmers University of Technology, Medical University in Vienna, Icahn School of Medicine at Mount Sinai and NYU Langone Health, with results published in The Lancet Digital Health. Lymphoma is a cancer of the lymphatic system, including the lymph nodes, spleen, thymus gland and bone marrow, and can affect other organs throughout the body. The two main subtypes of lymphoma are Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, which is the sixth most common cancer in the UK, responsible for around 14,200 cases every year, according to Cancer Research UK. Using AI-assisted image analysis of lymphoma, researchers developed a deep learning ...
The government has today announced action to tackle potential bias in the design and use of medical devices, as it accepts recommendations from a UK-first independent review. The Department of Health and Social Care commissioned senior health experts to identify potential biases in these devices and recommend how to tackle them. The government fully accepted the report’s conclusions and has made a series of commitments, including ensuring that pulse oximeter devices used in the NHS can be used safely across a range of skin tones, and removing racial bias from data sets used in clinical studies. Minister of State, Andrew Stephenson said: I am hugely grateful to Professor Dame Margaret Whitehead for carrying out this important review. Making sure the healthcare system works for everyone, regardless of ethnicity, is paramount to our values as a nation. It supports our wider work to create a fairer and simpler NHS. Ministers agree ...
The incidence and mortality rates of colorectal cancer (CRC) are on an alarming rise, with predictions showing a continuous increase until at least 2040. Currently, CRC ranks as the third most diagnosed (10.7% of all cancer cases) and the second deadliest cancer type. Despite the effectiveness of imaging and endoscopic techniques in CRC detection, the final cancer diagnosis always relies on a pathologist’s assessment of histological samples. Grading dysplasia is still routinely performed by pathologists worldwide when assessing colorectal tissue samples. Computer-aided diagnosis (CAD) systems for colorectal pathology face challenges due to the high data volume and the massive resolution of images, leading to a bottleneck in deep learning (DL) approaches that extract patches from the whole slides. Now, researchers at INESC TEC (Porto, Portugal) and IMP Diagnostics (Porto, Portugal) have created a pioneering prototype that employs artificial intelligence (AI) for colorectal diagnosis. This prototype is a result of a ...
AI remained one of the main talking points at CTS Europe, as the roadmap for generative AI was mapped out. In 2022, the launch of the generative Artificial Intelligence (AI) platform ChatGPT broke the record for the fastest-growing consumer application in history. Following the rapid adoption of AI technologies, the pharma sector is now exploring the capabilities and challenges of generative AI as it remains one of the key trends in the industry. However, despite the recent progress in the use of AI in real-world situations, we are still in the early stages of the AI roadmap, research director at GlobalData Josep Bori, at the recently concluded Clinical Trial Supply (CTS) Europe 2024 meeting. Generative AI is a technology capable of generating text, images or other data using generative models, often in response to prompts. Explaining how generative AI works, Bori said: “AI is trying to optimise the output to ...
The project will train a newly developed AI system on data collected from participating men and women Researchers from the University of Glasgow’s James Watt School of Engineering are aiming to ensure that artificial intelligence (AI)-based healthcare monitoring systems in the future are free of gender bias, to improve care for both men and women. For 18 months, the project will examine the potential for gender bias in healthcare AI and discover ways to ensure that AI-supported treatment remains equitable. The use of cutting-edge sensors is currently being investigated to track the rhythms of patients’ hearts and lungs without requiring them to wear monitoring devices or be recorded on video cameras. The team aims to address and ensure that its AI component is properly trained and capable of making the correct judgements without bias towards one gender of patients. Supported by £8,200 in funding from the Université Paris Dauphine-PSL’s Women ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.